Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Other Non-Current Assets (2019 - 2026)

Biodesix filings provide 8 years of Other Non-Current Assets readings, the most recent being $7.9 million for Q1 2026.

  • On a quarterly basis, Other Non-Current Assets rose 7.71% to $7.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.9 million, a 7.71% increase, with the full-year FY2025 number at $8.2 million, up 13.36% from a year prior.
  • Other Non-Current Assets hit $7.9 million in Q1 2026 for Biodesix, down from $8.2 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $8.2 million in Q4 2025 to a low of $5100.0 in Q2 2022.
  • Median Other Non-Current Assets over the past 5 years was $6.9 million (2023), compared with a mean of $6.2 million.
  • Biggest five-year swings in Other Non-Current Assets: crashed 99.8% in 2022 and later surged 136919.61% in 2023.
  • Biodesix's Other Non-Current Assets stood at $5.9 million in 2022, then grew by 15.8% to $6.9 million in 2023, then increased by 5.85% to $7.3 million in 2024, then rose by 13.36% to $8.2 million in 2025, then dropped by 4.46% to $7.9 million in 2026.
  • The last three reported values for Other Non-Current Assets were $7.9 million (Q1 2026), $8.2 million (Q4 2025), and $7.5 million (Q3 2025) per Business Quant data.